RisCassi & Davis is currently investigating cases on behalf of women who have developed meningiomas after using Depo-Provera for a year or more.
Why This Matters
A recent French study published in The British Medical Journal has found a potential link between prolonged use of Depo-Provera (medroxyprogesterone acetate) and an increased risk of developing meningiomas that require surgical intervention. The study, which analyzed data from over 100,000 women, revealed a 5.55% increased risk of meningiomas with one year or more of Depo-Provera use. This fact is concerning as approximately 1 in 5 women have used Depo-Provera at some point in their lives.
Depo-Provera is a contraceptive injection that contains a synthetic form of the hormone progesterone. It is typically administered every three months and is also used to treat conditions like endometriosis, abnormal uterine bleeding, and ovarian cysts. In the U.S., between 1 to 2 million women use Depo-Provera annually.
Meningiomas are typically benign tumors that develop in the brain or spine, but their size and location can lead to serious health complications. Common symptoms include headaches, vision changes, seizures, hearing loss, and neurological issues. Treatment for meningiomas usually involves surgery, though radiation therapy is sometimes an option.
RisCassi & Davis Is Here to Help
Our product liability attorneys have assisted people who pharmaceutical drugs have injured for close to 70 years. And we have received meaningful state and national recognition for our work in this area. We have offices in Avon, Glastonbury, Hartford, and Middletown. The consultation is free and there is no obligation.
If you would like to talk with one of our attorneys about your use of Depo-Provera, please get in touch with us.